Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GNF-4256 |
| Synonyms | |
| Therapy Description |
GNF-4256 inhibits TRK receptor activation, potentially resulting in decreased tumor growth (PMID: 25394774). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GNF-4256 | Trk Receptor Inhibitor (Pan) 33 | GNF-4256 inhibits TRK receptor activation, potentially resulting in decreased tumor growth (PMID: 25394774). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NTRK2 loss | neuroblastoma | no benefit | GNF-4256 | Preclinical | Actionable | In a preclinical study, GNF-4256 treatment had no effect on the growth of Ntrk2-null neuroblastoma cell lines in culture (PMID: 25394774). | 25394774 |
| NTRK2 positive | neuroblastoma | sensitive | GNF-4256 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, GNF-4256 treatment inhibited BDNF-induced phosphorylation of Ntrk2 and growth of neuroblastoma cell lines expressing Ntrk2 in culture, and slowed tumor growth in the neuroblastoma cell line xenograft models (PMID: 25394774). | 25394774 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|